Duchenne muscular dystrophy (DMD) is a severe progressive X-linked neuromuscular illness that affects movement through mutations in dystrophin gene. The mutation leads to insufficient, lack of, or dysfunction of dystrophin. The cause of DMD was determined in an Iranian family. Exome sequencing was carried out along with a complete physical examination of the family. In silico methods were applied to find the alteration in the protein structure. The homozygous variant in DMD gene (NM-004006.2) was defined as c.2732-2733delTT (p.Phe911CysfsX8) in exon 21. In addition, phylogenetic conservation study of the human dystrophin protein sequence revealed that phenylalanine 911 is one of the evolutionarily conserved amino acids. In conclusion, our study indicated a new deletion in the DMD gene in the affected family. This deletion with an X-linked inheritance pattern is new in Iran. These findings could facilitate genetic counseling for this family and other patients in the future.
Get full access to this article
View all access options for this article.
References
1.
Amiri-DashatanN., KoushkiM., ParsamaneshN., and ChitiH. (2022). Serum cortisol concentration and COVID-19 severity: a systematic review and meta-analysis. J Invest Med, 70, 766–772.
2.
BushbyK., FinkelR., BirnkrantD.J., CaseL.E., ClemensP.R., CripeL., et al. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol, 9, 77–93.
3.
CapriottiE., AltmanR.B., and BrombergY. (2013). Collective judgment predicts disease-associated single nucleotide variants. BMC Genom, 14, 1–9.
4.
CiafaloniE., FoxD.J., PandyaS., et al. (2009). Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr, 155, 380–385.
5.
CirakS., Arechavala-GomezaV., GuglieriM., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595–605.
6.
CordovaG., NegroniE., Cabello-VerrugioC., MoulyV., and TrolletC. (2018). Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy. Front Genet 9,114.
7.
DerakhshaniA., MollaeiH., ParsamaneshN., et al. (2020). Gene co-expression network analysis for identifying modules and functionally enriched pathways in vitiligo disease: A systems biology study. Iran J Allergy Asthma Immunol, 19, 517–528.
8.
FalzaranoM.S., ScottonC., PassarelliC., and FerliniA. (2015). Duchenne muscular dystrophy: from diagnosis to therapy. Molecules, 20, 18168–18184.
9.
FerliniA., NeriM., and GualandiF. (2013). The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscular Disord, 23, 4–14.
10.
GuiraudS., ChenH., BurnsD.T., and DaviesK.E. (2015). Advances in genetic therapeutic strategies for Duchenne muscular dystrophy. Exp Physiol, 100, 1458–1467.
11.
KohliS., SaxenaR., ThomasE., et al. (2020). Mutation spectrum of dystrophinopathies in India: Implications for therapy. Indian J Pediatr, 87, 495–504.
12.
LimB.C., LeeS., ShinJ.-Y. (2011). Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform. J Med Genet, 48, 731–736.
13.
LjubicicV., BurtM., and JasminB.J. (2014). The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets. FASEB J, 28, 548–568.
14.
MohamadianM., ParsamaneshN., ChitiH., SathyapalanT., and SahebkarA. (2022). Protective effects of curcumin on ischemia/reperfusion injury. Phytother Res, 36, 4299–4324.
15.
NunesM.F., HukudaM.E., FaveroF.M., OliveiraA.B., VoosM.C., and CaromanoF.A. (2016). Relationship between muscle strength and motor function in Duchenne muscular dystrophy. Arquivos Neuro Psiquiatr, 74, 530–535.
16.
OguraY., TajrishiM.M., SatoS., HindiS.M., and KumarA. (2014). Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol 2,11.
17.
ParsamaneshN., MoossaviM., TavakkoliT., et al. (2019a). Positive correlation between vitamin D receptor gene TaqI variant and gastric cancer predisposition in a sample of Iranian population. J Cell Physiol, 234, 15044–15047.
18.
ParsamaneshN., SafarpourH., EtesamS., ShadmehriA.A., and Miri-MoghaddamE. (2019b). Identification and in silico characterization of a novel point mutation within the phosphatidylinositol glycan anchor biosynthesis class G gene in an Iranian family with intellectual disability. J Mol Neurosci, 69, 538–545.
19.
Roshan-MilaniS., SeyyedabadiB., SabooryE., ParsamaneshN., and MehranfardN. (2021). Prenatal stress and increased susceptibility to anxiety-like behaviors: role of neuroinflammation and balance between GABAergic and glutamatergic transmission. Stress, 24, 481–495.
20.
RyderS., LeadleyR., ArmstrongN., et al. (2017). The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphan J Rare Dis, 12, 1–21.
21.
SaravaniS., ParsamaneshN., and Miri-MoghaddamE. (2020). Role of EGFR gene polymorphisms in oral squamous cell carcinoma patients of Southeast Iran: A case-control study. Casp J Intern Med 11,391.
22.
SteinM.T., TipnisN.A., and SchultzP. (2004). Fatigue, decreased interest in play, motor delay, and elevated liver function tests in a 4-year-old boy. J Dev Behav Pediatr, 25, S38–S42.
23.
WangL., XuM., LiH., et al. (2019). Genotypes and phenotypes of DMD small mutations in Chinese patients with dystrophinopathies. Front Genet 10,114.
24.
WangY., YangY., LiuJ., et al. (2014). Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. Mol Genet Genom, 289, 1013–1021.
25.
WangZ., TapscottS.J., ChamberlainJ.S., and StorbR. (2011). Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front Microbiol 2,201.
26.
XieS., LanZ., QuN., et al. (2012). Detection of truncated dystrophin lacking the C-terminal domain in a Chinese pedigree by next-generation sequencing. Gene, 499, 139–142.
